Sources discussed here
The experiments have different jobs here. The animal work raises the puzzle; the human studies ask more specific questions about cognition, structure and consequences.
Agonist and antagonist experiments
The MIA-690 antagonist paper and the MR-409 agonist paper supply the central disagreement. Both include animal and cell work, with different interventions. The GHRH review gives the broader pharmacological context.
Human studies and the editorial
The tesamorelin cognition trial tests an intervention in older adults. The congenital-deficiency MRI study compares untreated adults with matched controls. Their differing questions make the pairing productive in my estimation.
For the consequences elsewhere in the body, read the PEG-conjugated GHRH study beside the age-advanced men-and-women study. The secretagogue editorial supplies an objection to the broader anti-aging use.
- Beneficial effects of novel antagonists of GHRH in different models of Alzheimer's disease. ↗
- Growth hormone-releasing hormone attenuates amyloid deposition and neuroinflammation in Alzheimer's disease models. ↗
- Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial ↗
- Brain morphometry and estimation of aging brain in subjects with congenital untreated isolated GH deficiency. ↗
- Polyethylene glycol-conjugated growth hormone-releasing hormone is long acting and stimulates GH in healthy young and elderly subjects. ↗
- Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. ↗
- Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time ↗
- Growth hormone-releasing hormone and its analogues in health and disease ↗